Review on Drug induced hematological disorder.

Authors

  • Roshan B. Badhe Student, Department of Pharmacy, Ahinsa Institute of Pharmacy, Dhule Road, Dondaicha, India.
  • Samiksha Amrutkar Student, Department of Pharmacy, Ahinsa Institute of Pharmacy, Dhule Road, Dondaicha, India.

DOI:

https://doi.org/10.37591/rrjodfdp.v10i2.1344

Keywords:

Drug-induced anemia, aplastic anemia, agranulocytosis, hemolytic anemia, megaloblastic anemia, thrombocytopenia, pure blood cell hypoplasia, eosinophilia. Sideroblastic anemia.

Abstract

Drugs have the potential to profoundly impact not just the bone marrow, but also the entire spectrum of peripheral blood cells, leading to a wide array of hematologic disorders. These pharmaceutical-induced conditions can affect white blood cells, red blood cells, platelets, and the coagulation system, posing a significant risk in modern pharmacotherapy. Among the drug-induced syndromes, some noteworthy examples include aplastic anemia, agranulocytosis, hemolytic anemia, megaloblastic anemia, thrombocytopenia, methemoglobinemia, sideroblastic anemia, and pure blood cell aplasia. These drug-related hematologic complications underscore the importance of careful monitoring and vigilant management when prescribing and using medications, as they can potentially be life-threatening.

References

Lubran, MICHAEL M. "Hematologic side effects of drugs." Annals of Clinical & Laboratory Science 19.2 (1989): 114-121.

Scheinberg, Phillip, and Neal S. Young. "How I treat acquired aplastic anemia." Blood, The Journal of the American Society of Hematology 120.6 (2012): 1185-1196.

Brodsky, Robert A., and Richard J. Jones. "Aplastic anaemia." The Lancet 365, no. 9471 (2005): 1647-165.

A M Gewirtz, R Hoffman. Current considerations of the etiology of aplastic anemia. Crit Rev Oncol Hematol 1985; 4:1–30.

N S Young, R T Calado, and P Scheinberg. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509–19.

Roger Walker. Clinical Pharmacy and Therapeutics. 2012; 5th edition: 655-663.

G. Garratty and P. A. Arndt, An update on drug-induced immune hemolyticanemia, Immunohematology, 2007; 23(2): 105–119.

Amit Kumar, V N Jha and Nimisha. Megaloblastic Anemia – An Underdiagnosed Public Health Problem. World Journal of Pharmaceutical and Medical Research 2018,4(2), 100-101

K C Das, Das Monisha and D Mohanty, M.M Jadaon, A Gupta Megaloblastosis: from morphos tomolecules. Med PrincPract 2005; 14: (Suppl 1): 2-14.

N L Kobrinsky and N K Ramsay. Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole. Ann Intern Med 1981; 94: 780- 781.

F Magee, O’H Sullivan and S R McCann. Megaloblastosis and lowdose trimethoprim-sulfamethoxazole. Ann Intern Med 1981; 95: 657-661.

N Patel, H Vandewall, and L Tristani. A comparative evaluation of adverse platelet outcomes among Veterans’ Affairs patients receiving linezolid or vancomycin. J AntimicrobChemother 2012;67(3):725–735 13.N.James George and H Richard. AsterDruginduced thrombocyte-penia: pathogenesis, evaluation, and management. Hematology (Am SocHematolEduc Program) 2009: 153– 158

B Kenney and Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133(2): 309–31

N Frickhofen, Z J Chen, N S Young, B J Cohen, H Heimpel and J L Abkowitz. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol. 1994;87(4):818-24.

B Saikia, H Aneja, A Manchanda, R Patowary and B Barman. Carbamazepine-induced Pure Red Cell Aplasia in a Young Girl. Indian Journal of Medical Specialities Trust 2010; 1(2): 130- 133

R A Sharma, P Hiwarkar, M V Manglani and H P Muralidhar. Acquired pure red cell aplasia in a child. J Postgrad Med, 2002; 48: 37-38

Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15;106(10):3343-7.6.

Topal, Hatice, and Yasar Topal. "Toxic methemoglobinemia treated with ascorbic acid: Case report." Iranian Red Crescent Medical Journal 15, no. 12 (2013).

Alcindor, Thierry, and Kenneth R. Bridges. "Sideroblastic anaemias." British journal of haematology 116, no. 4 (2002): 733-743.

R. A. Sharp, J. G. Lowe and R. N. Johnston, “Anti-tuberculousdrugs and sideroblastic anaemia,” British Journal of Clinical Practice, 1990; 44 (12). 7 06–707.

S Ammus and A A.Yunis. Druginduced red cell dyscrasias.Blood Rev. 1989;3(2):71-82.

L A Fernandez and E Zayed.Busulfan-induced sideroblasticanemia. Am J Hematol. 1988; 28(3):199–200.

L Kandola, A J Swannell, and A HunterAcquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis.Ann Rheum Dis. 1995; 54(6): 529–530.

Downloads

Published

2023-11-16

Issue

Vol. 10 No. 2 (2023)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.